University of California, San Francisco
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of California, San Francisco sits in the top decile of US sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count).
University of California, San Francisco: 1,713 sponsored US clinical trials, 272 recruiting.
University of California, San Francisco sponsors 1,713 registered US clinical trials on ClinicalTrials.gov, 272 of them currently recruiting, and 1,130 completed. 196 of these trials are in Phase 3-4 (later-stage) and 359 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 18 trials.
Top-decile sponsor footprint
University of California, San Francisco ranks in the top decile of sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,130 of 1,305 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,713 total, page 2 of 35
Technology Assisted Motivational Interviewing
NCT06713603
Adding Urea to the Final Dialysis Fluid
NCT06366230
A Study to Evaluate Community-Based Measures to Increase RSV Vaccine Use Among Latino Adults
NCT07171164
Study for Remote Investigation of Evaporative Dry Eye Disease
NCT06976515
Reporting Back Pesticide Results to Family Child Care Home Directors
NCT06910462
Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A
NCT06658002
Wellness, Intervention Strategies and HIV Care
NCT07069374
BID LTM Digital Intervention in Aging
NCT06916221
BID WM Digital Intervention in Aging
NCT06918704
Oral vs IV Sedation for Cataract Surgery in Older Adults
NCT07154147
Contingency Management for Veteran Smokers Undergoing Major Elective Surgery
NCT06678672
Pediatric Metabolic Dysfunction-associated Steatotic Liver Disease and Food Insecurity
NCT07090083
Food Insecurity and MASLD: A Fruit and Vegetable Intervention Study
NCT07091539
Gauging Outcomes of Total Milk Ingestion on Lipid and gControl
NCT07087184
Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients
NCT06798909
Non-Invasive Low Intensity Focused Ultrasound Stimulation for Drug-Resistant Epilepsy
NCT07680842
The ROAR Study: Reactive Oxygen Species and Reproduction
NCT06831019
Effect of Magnesium on Neuromonitoring
NCT06975072
Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration
NCT05999383
Healthy Family Project: Tobacco Use and Smoke Exposure in Asian American Communities
NCT07049757
Central micrOperimetry and Radial OCT Evaluation in Geographic Atrophy (CORE-GA): a Prospective Pilot Study
NCT07556406
The Effect of Erector Spinae Plane Block (ESPB) on Pediatric Pain Management Following Posterior Spinal Fusion (PSF) Surgery
NCT07561827
Treating Adolescent Obsessive Compulsive Disorder With Transcranial Magnetic Stimulation
NCT07065669
Probiotic Administration for Adolescent Depression
NCT06898788
Supportive Training After Cardiac Rehabilitation Including Virtual Engagement
NCT06701188
National Program to Overcome Pelvic Pain studY (POPPY)
NCT06778070
Sodium in the Skin and Atopic Dermatitis
NCT06998446
Natural History of Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS)
NCT06669949
SPL Insufficiency Syndrome (SPLIS)/NPHS14: a SPLIS Observational Study and Patient Registry (International)
NCT04885179
Digitally Rendered Interventions And Knowledge To Limit Ethanol-Associated Atrial Fibrillation Severity
NCT06995391
Using Clinical Decision Support to Provide Social Risk-Informed Care for Opioid Use Disorder in the Emergency Department
NCT06872190
Full-Avoidance vs. Permissive/Regulated Drinking & Outcomes On Fibrillation
NCT06754176
Integrating Nonpharmacologic Strategies for Pain With Inclusion, Respect, and Equity
NCT06183281
Naltrexone for Overdose Prevention
NCT06633900
Wearable Activity Tracking to Curb Hospitalizations
NCT06587100
The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery
NCT06802224
IL1 Inhibition in FOP
NCT06724562
Integrative Approaches for Cancer Survivorship (IACS3)
NCT06633926
Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer
NCT06470282
Inflammatory Challenge and Fear
NCT06630884
Exercise and Movement to Enhance Resiliency in Cancer Patients
NCT06809933
Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma
NCT06682442
Cannabis THC Potency, Metabolism, and Cognitive Impairment in Young Adults
NCT06077292
Commercial or Open Source Closed Loop Impact on Pregnancy Study
NCT06654713
Embryonal Tumor With Multilayered Rosettes
NCT06861244
I CAN DO Surgical ACP
NCT06090552
FDG PET/MRI Imaging of Patellofemoral Joint Osteoarthritis
NCT07625150
Role of Transposable Elements in Septic Immune Aging
NCT06809868
People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity
NCT06055868
Research on Equity in Abortion Care by TeleHealth
NCT06787274
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 193 |
| Phase 2 | 166 |
| Phase 3 | 44 |
| Phase 4 | 152 |
Therapeutic Areas
What is open in the University of California, San Francisco pipeline
272 recruiting of 1,713 indexed (16% open); 1,130 completed (66%).
Phase mix: 196 late (III/IV) vs 359 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (18 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of California, San Francisco: open-pipeline peers nationwide
Peers matched on 1,713 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,713 trials (± recruiting share)
- Duke University · 1,725 trials · 11% recruiting
- Stanford University · 1,744 trials · 15% recruiting
- VA Office of Research and Development · 1,668 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
Sponsors near 16% open enrollment (± trial volume)
- University of Oregon · 16% recruiting · 63 trials
- Fox Chase Cancer Center · 16% recruiting · 183 trials
- Youngstown State University · 16% recruiting · 19 trials
- ECOG-ACRIN Cancer Research Group · 16% recruiting · 75 trials
Related
What to do with this University of California, San Francisco page
1,713 registered trials is a research-attention snapshot, not an endorsement of University of California, San Francisco or any single study.
- 272 of University of California, San Francisco's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition University of California, San Francisco studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of California, San Francisco pipeline card: 1,713 registered trials from official public datasets.Report a data error.